Global Interstitial Lung Disease Treatment Market Overview

Global Interstitial Lung Disease Treatment Market was valued at USD 1.63 Billion in 2021 and is expected to reach USD 2.48 Billion by the year 2028, at a CAGR of 6.2%.

Lungs are pair of spongy organs that are responsible for the exchange of gases in the human body. Lungs are located on either side of the chest and are protected by the rib cage. The air inhaled goes through the windpipe, bronchi, bronchioles, and then into microscopic air sacs called alveoli. These alveoli perform the important function in the lungs of exchange of carbon dioxide-a waste product of metabolism, and inhaled oxygen. In between these alveoli is a thin layer of cells called interstitium which contains blood vessels and cells that support alveoli. Interstitial lung disease (ILD) is a broad term for a large group of diseases that cause scarring (fibrosis) in the lungs. The scarring causes stiffness in the lungs which makes it difficult to breathe thus, it reduces the amount of oxygen in the bloodstream. Lung damage from ILDs is mostly irreversible and gets worse over time. Interstitial lung disease can affect any age group, including children. Various factors can increase the risk of or can cause ILDs such as genetics, medical treatments such as radiation or chemotherapy, or certain medications. The most common symptom of interstitial lung disease is shortness of breath and dry coughing. Air pollution can also trigger the rise in the number of individuals suffering from ILDs thus, stimulating the growth of the ILD treatment market in the forecast period.

Market Dynamics and Key Factors of Interstitial Lung Disease Treatment:

Drivers:

Interstitial lung diseases are caused by more than 200 factors. Individuals suffering from autoimmune disorders such as lupus, scleroderma, polymyositis/dermatomyositis, and rheumatoid arthritis may also develop ILDs. In autoimmune disorders, an individual’s immune system attacks the lungs that resulting in scarring of lungs, thus impairing the functioning of the lungs. Moreover, people working in the coal and asbestos field inhale thousands of small particulate substances. People working in these fields for a longer duration have a high chance of developing ILDs in their lifetime. In addition, people who breathe harmful gases such as tobacco smoke or hairdressing chemicals may also develop ILDs.

In genetic ILD, the disease is inherited from parents to their offspring and these conditions mostly include neurofibromatosis and Gaucher disease. The growing prevalence of autoimmune disorders and the rise in the smoking population are the two essential factors expected to stimulate the expansion of the interstitial lung disease treatment market in the forecast period. People are becoming more aware of the various treatment methods that can help resolve other complications associated with ILDs. Individuals over 50 years of age are more susceptible to ILDs as compared to other age groups. Over the past decade, there has been a significant rise in the geriatric population thus, the demand for treatment of ILD is expected to exponentially grow in the forecasted period. The rise in the adoption of interstitial lung disease treatment methods coupled with the growing R&D activities is expected to support the expansion of the market in the projected period.

Restraints:

Unawareness about the benefits of interstitial lung disease treatment and the negligence shown by individuals towards screening methods to diagnose ILDs are the essential factors that are hindering the expansion of the market in the forecast period. Furthermore, people taking oral medications may suffer from certain allergic reactions which can exaggerate the disease condition. Cyclophosphamide a drug administered in the treatment of ILDs can cause damage to the bladder, immunosuppression, and alopecia thus, complications associated with the treatment methods may hamper the development of the market in the projected timeframe.

Opportunities:

Air pollution has been a matter of concern for all countries across the globe. Various harmful substances are released into the atmosphere due to the burning of coal, tobacco, and other materials which results in the development of ILDs in people who have a weak immune system. According to Scientific American, 4.5% of the total world population is affected by autoimmune disorders. As autoimmune individuals are more susceptible to ILDs it is expected that it will create a profitable opportunity for the market players to discover novel drugs that can treat both the autoimmune disorder and ILD. Furthermore, the majority of the population suffering from ILDs lives in developing regions. Manufacturers can target these regions to increase their revenue and launch new products in these markets to meet the needs of patients in this region, and make treatment of ILDs affordable. Supportive government policies and voluntary participation of candidates for trials of novel drugs are the essential factors that are expected to generate a lucrative opportunity for the market players.

Market Segmentation For ILD Treatment

Depending on the diagnosis, the CT scan segment is anticipated to have the highest share of the ILD treatment market throughout the forecast period. CT scanners utilize a computer to combine X-ray images that are taken from different angles to produce a cross-sectional image of internal structures. A high-resolution CT (HRCT) scan can help in evaluating the extent of the lung damage caused by ILDs. In addition, a CT scan can show the detailed spread of the fibrosis, which can assist the healthcare provider in narrowing down the diagnosis and in guiding appropriate treatment. The growing popularity of HRCT among healthcare providers to detect the early signs of ILDs is expected to support the development of this segment in the forecast period.

Depending on the disease type, the sarcoidosis form of the disease is expected to be more prevalent in the projected period. Sarcoidosis is an inflammatory disease that causes the immune system to overreact, resulting in the formation of inflamed tissue called granulomas in the lungs and lymph nodes. According to the Sarcoidosis Research Foundation, about 200,000 cases are diagnosed annually in the United States. Individuals of any age group are susceptible to sarcoidosis but people of African and Scandinavian descent are more at risk.

Depending on the treatment, the corticosteroids segment is predicted to lead the ILDs market in the analysis period. Corticosteroids are often the most common first medication administered to treat many forms of ILDs. Corticosteroids are widely administered along with other drugs that are mainly immunosuppressants. Depending on the cause of the ILDs, this combination can stabilize or even slow down the progression of the disease. Corticosteroids reduce inflammation in the lung thus, making it easier for the patient to breathe thus, consolidating the expansion of the segment in the projected period.

Depending on the route of administration, the oral segment is expected to lead the ILDs treatment market throughout the projected period. Oral medications are most proffered by patients as these can be easily self-administered. Oral drugs are simple to consume, convenient, and non-invasive. Additionally, oral medications are less costly as compared to other forms of medications, thus supporting the growth of the segment. 

Players Covered in Interstitial Lung Disease Treatment market are :

• F. Hoffman - La Roche Ltd (Switzerland)
• Merck Sharp & Dohme Corp. (US)
• Boehringer Ingelheim International GmbH (Germany)
• J.B. Chemicals & Pharmaceutical (India)
• Galecto Inc (Denmark)
• Cipla Ltd (India)
• Glenmark Pharma (India)
• Gilead Sciences Inc (US)
• Bristol-Myers Squibb Company (US)
• FibroGen Inc (US)
• Liminal Biosciences (Canada) and others major players.

Regional Analysis of Interstitial Lung Disease Treatment Market:

The North American region is anticipated to dominate the ILD treatment market during the forecast period attributed to the presence of prominent manufacturers in this region. Idiopathic pulmonary fibrosis (IPF) is the most common form of ILD. About 15-20 people per 100,000 people are suffering from IPF worldwide. According to Medline Plus, 100,000 Americans are affected by ILD and around 30,000 to 40,000 cases are diagnosed every year in the United States. Moreover, 39,000 American lives succumbed to Asbestosis in the USA every year. Thus, the increasing number of individuals suffering from ILD is supporting the development of the market in this region.

The European region is expected to have the second-highest share of the ILD treatment market in the projected period. The growing air pollution and the rise in the number of smokers in this region are expected to fuel the growth of the ILD treatment market. According to Eurostat, 18.4% of the EU population aged over 15 years smoke tobacco daily. The smoker’s population is high in Bulgaria (28.7%), Greece (23.6%), Latvia (22.1%), Germany (21.9%), and Croatia (21.8%). Smoking tobacco is one of the main factors that promote the development of ILD in individuals thus, the gradual rise in the smoking population will elevate the number of ILD patients and hence will aid in the expansion of the market.

The ILD treatment market in the Asia-Pacific region is anticipated to develop at the highest CAGR during the projected period attributed to the legal as well as illegal mining of asbestos. Since the early 1970s more than 50 countries put a ban on mining activities of asbestos. Even though the popularity of asbestos in developing nations is growing over the years attributed to the aggressive industry campaigns. Additionally, asbestos is affordable as well the mass production of building material is high in demand in this region. Thus, the growing usage of asbestos is stimulating the rise in the number of patients suffering from ILD. According to the National Health Portal of India, approximately 107,000 people die each year due to asbestos-related diseases thus, driving the growth of the market.

Recent Industry Developments in Interstitial Lung Disease Treatment Market:

• In March 2021, Roche announced that Actemra/RoActemra (tocilizumab) subcutaneous injection has been approved by the US Food and Drug Administration (FDA) for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with few treatment options. The FDA has authorized Actemra/RoActemra as the first biologic medication for the treatment of the condition.
• In April 2021, Boehringer Ingelheim announced that The European Commission has authorized nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults. The approval comes after the Committee for Medicinal Products for Human Use issued a favorable opinion for nintedanib in the treatment of SSc-ILD on 27 February 2020.

COVID-19 Impact on Interstitial Lung Disease Treatment Market:

The outbreak of COVID-19 adversely impacted the functioning of several industry verticals. Healthcare facilities were under tremendous stress due to the continuously rising number of patients. According to several economic indices, the COVID-19 pandemic disrupted the world economy. Numerous international trade and economic activities were halted or postponed during the pandemic. For instance, several countries imposed a ban on exports and import activities. In addition, the restrictions on transportation resulted in a shortage of materials required for the manufacturing of drugs utilized to treat ILDs. Moreover, during the pandemic period, it became difficult for pharmaceutical companies to recruit candidates for clinical trials of several pipeline drugs. These included the clinical trials of drugs focused on the treatment of various ILDs. The COVID-19 protocol such as lockdown prevented participants to visit the clinical sites. Furthermore, COVID-19 hampered the clinical studies as participants were unwilling to visit the clinical sites due to the fear of being getting infected with the virus. COVID-19 pandemic boosted telemedicine consultations, delayed screening procedure, interrupted supply of medications, and a decrease in the parenteral medication delivery was observed. To summarize, the COVID-19 pandemic negatively affected the clinical trials of various pipeline drugs that were developed for the treatment of ILDs.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Disease Type
 3.3 By Treatment
 3.4 By Route Of Administration

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Interstitial Lung Disease Treatment Market by Type
 5.1 Interstitial Lung Disease Treatment Market Overview Snapshot and Growth Engine
 5.2 Interstitial Lung Disease Treatment Market Overview
 5.3 Imaging Tests
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Imaging Tests: Grographic Segmentation
 5.4 Blood Tests
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Blood Tests: Grographic Segmentation
 5.5 Lung Function Tests
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Lung Function Tests: Grographic Segmentation
 5.6 Lung Biopsy
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Lung Biopsy: Grographic Segmentation
 5.7 Others
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Others: Grographic Segmentation

Chapter 6: Interstitial Lung Disease Treatment Market by Disease Type
 6.1 Interstitial Lung Disease Treatment Market Overview Snapshot and Growth Engine
 6.2 Interstitial Lung Disease Treatment Market Overview
 6.3 Interstitial Pneumonia
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Interstitial Pneumonia: Grographic Segmentation
 6.4 Idiopathic Pulmonary Fibrosis
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Idiopathic Pulmonary Fibrosis: Grographic Segmentation
 6.5 Hypersensitivity Pneumonitis
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Hypersensitivity Pneumonitis: Grographic Segmentation
 6.6 Sarcoidosis
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Sarcoidosis: Grographic Segmentation
 6.7 Asbestosis
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Asbestosis: Grographic Segmentation

Chapter 7: Interstitial Lung Disease Treatment Market by Treatment
 7.1 Interstitial Lung Disease Treatment Market Overview Snapshot and Growth Engine
 7.2 Interstitial Lung Disease Treatment Market Overview
 7.3 Medications
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Medications: Grographic Segmentation
 7.4 Pulmonary Rehabilitation
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Pulmonary Rehabilitation: Grographic Segmentation
 7.5 Oxygen Therapy
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Oxygen Therapy: Grographic Segmentation
 7.6 Surgery
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size (2016-2028F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Surgery: Grographic Segmentation

Chapter 8: Interstitial Lung Disease Treatment Market by Route Of Administration
 8.1 Interstitial Lung Disease Treatment Market Overview Snapshot and Growth Engine
 8.2 Interstitial Lung Disease Treatment Market Overview
 8.3 Oral
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size (2016-2028F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Oral: Grographic Segmentation
 8.4 Injectable
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size (2016-2028F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Injectable: Grographic Segmentation
 8.5 Others
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size (2016-2028F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Others: Grographic Segmentation

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Positioning
  9.1.2 Interstitial Lung Disease Treatment Sales and Market Share By Players
  9.1.3 Industry BCG Matrix
  9.1.4 Ansoff Matrix
  9.1.5 Interstitial Lung Disease Treatment Industry Concentration Ratio (CR5 and HHI)
  9.1.6 Top 5 Interstitial Lung Disease Treatment Players Market Share
  9.1.7 Mergers and Acquisitions
  9.1.8 Business Strategies By Top Players
 9.2 F. HOFFMAN - LA ROCHE LTD.
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Operating Business Segments
  9.2.5 Product Portfolio
  9.2.6 Business Performance
  9.2.7 Key Strategic Moves and Recent Developments
  9.2.8 SWOT Analysis
 9.3 MERCK SHARP & DOHME CORP.
 9.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 9.5 J.B. CHEMICALS & PHARMACEUTICAL
 9.6 GALECTO INC.
 9.7 CIPLA LTD.
 9.8 GLENMARK PHARMA
 9.9 GILEAD SCIENCES INC.
 9.10 BRISTOL-MYERS SQUIBB COMPANY
 9.11 FIBROGEN INC.
 9.12 LIMINAL BIOSCIENCES
 9.13 OTHERS MAJOR PLAYERS

Chapter 10: Global Interstitial Lung Disease Treatment Market Analysis, Insights and Forecast, 2016-2028
 10.1 Market Overview
 10.2 Historic and Forecasted Market Size By Type
  10.2.1 Imaging Tests
  10.2.2 Blood Tests
  10.2.3 Lung Function Tests
  10.2.4 Lung Biopsy
  10.2.5 Others
 10.3 Historic and Forecasted Market Size By Disease Type
  10.3.1 Interstitial Pneumonia
  10.3.2 Idiopathic Pulmonary Fibrosis
  10.3.3 Hypersensitivity Pneumonitis
  10.3.4 Sarcoidosis
  10.3.5 Asbestosis
 10.4 Historic and Forecasted Market Size By Treatment
  10.4.1 Medications
  10.4.2 Pulmonary Rehabilitation
  10.4.3 Oxygen Therapy
  10.4.4 Surgery
 10.5 Historic and Forecasted Market Size By Route Of Administration
  10.5.1 Oral
  10.5.2 Injectable
  10.5.3 Others

Chapter 11: North America Interstitial Lung Disease Treatment Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Imaging Tests
  11.4.2 Blood Tests
  11.4.3 Lung Function Tests
  11.4.4 Lung Biopsy
  11.4.5 Others
 11.5 Historic and Forecasted Market Size By Disease Type
  11.5.1 Interstitial Pneumonia
  11.5.2 Idiopathic Pulmonary Fibrosis
  11.5.3 Hypersensitivity Pneumonitis
  11.5.4 Sarcoidosis
  11.5.5 Asbestosis
 11.6 Historic and Forecasted Market Size By Treatment
  11.6.1 Medications
  11.6.2 Pulmonary Rehabilitation
  11.6.3 Oxygen Therapy
  11.6.4 Surgery
 11.7 Historic and Forecasted Market Size By Route Of Administration
  11.7.1 Oral
  11.7.2 Injectable
  11.7.3 Others
 11.8 Historic and Forecast Market Size by Country
  11.8.1 U.S.
  11.8.2 Canada
  11.8.3 Mexico

Chapter 12: Europe Interstitial Lung Disease Treatment Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Imaging Tests
  12.4.2 Blood Tests
  12.4.3 Lung Function Tests
  12.4.4 Lung Biopsy
  12.4.5 Others
 12.5 Historic and Forecasted Market Size By Disease Type
  12.5.1 Interstitial Pneumonia
  12.5.2 Idiopathic Pulmonary Fibrosis
  12.5.3 Hypersensitivity Pneumonitis
  12.5.4 Sarcoidosis
  12.5.5 Asbestosis
 12.6 Historic and Forecasted Market Size By Treatment
  12.6.1 Medications
  12.6.2 Pulmonary Rehabilitation
  12.6.3 Oxygen Therapy
  12.6.4 Surgery
 12.7 Historic and Forecasted Market Size By Route Of Administration
  12.7.1 Oral
  12.7.2 Injectable
  12.7.3 Others
 12.8 Historic and Forecast Market Size by Country
  12.8.1 Germany
  12.8.2 U.K.
  12.8.3 France
  12.8.4 Italy
  12.8.5 Russia
  12.8.6 Spain
  12.8.7 Rest of Europe

Chapter 13: Asia-Pacific Interstitial Lung Disease Treatment Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Imaging Tests
  13.4.2 Blood Tests
  13.4.3 Lung Function Tests
  13.4.4 Lung Biopsy
  13.4.5 Others
 13.5 Historic and Forecasted Market Size By Disease Type
  13.5.1 Interstitial Pneumonia
  13.5.2 Idiopathic Pulmonary Fibrosis
  13.5.3 Hypersensitivity Pneumonitis
  13.5.4 Sarcoidosis
  13.5.5 Asbestosis
 13.6 Historic and Forecasted Market Size By Treatment
  13.6.1 Medications
  13.6.2 Pulmonary Rehabilitation
  13.6.3 Oxygen Therapy
  13.6.4 Surgery
 13.7 Historic and Forecasted Market Size By Route Of Administration
  13.7.1 Oral
  13.7.2 Injectable
  13.7.3 Others
 13.8 Historic and Forecast Market Size by Country
  13.8.1 China
  13.8.2 India
  13.8.3 Japan
  13.8.4 Singapore
  13.8.5 Australia
  13.8.6 New Zealand
  13.8.7 Rest of APAC

Chapter 14: Middle East & Africa Interstitial Lung Disease Treatment Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Type
  14.4.1 Imaging Tests
  14.4.2 Blood Tests
  14.4.3 Lung Function Tests
  14.4.4 Lung Biopsy
  14.4.5 Others
 14.5 Historic and Forecasted Market Size By Disease Type
  14.5.1 Interstitial Pneumonia
  14.5.2 Idiopathic Pulmonary Fibrosis
  14.5.3 Hypersensitivity Pneumonitis
  14.5.4 Sarcoidosis
  14.5.5 Asbestosis
 14.6 Historic and Forecasted Market Size By Treatment
  14.6.1 Medications
  14.6.2 Pulmonary Rehabilitation
  14.6.3 Oxygen Therapy
  14.6.4 Surgery
 14.7 Historic and Forecasted Market Size By Route Of Administration
  14.7.1 Oral
  14.7.2 Injectable
  14.7.3 Others
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Turkey
  14.8.2 Saudi Arabia
  14.8.3 Iran
  14.8.4 UAE
  14.8.5 Africa
  14.8.6 Rest of MEA

Chapter 15: South America Interstitial Lung Disease Treatment Market Analysis, Insights and Forecast, 2016-2028
 15.1 Key Market Trends, Growth Factors and Opportunities
 15.2 Impact of Covid-19
 15.3 Key Players
 15.4 Key Market Trends, Growth Factors and Opportunities
 15.4 Historic and Forecasted Market Size By Type
  15.4.1 Imaging Tests
  15.4.2 Blood Tests
  15.4.3 Lung Function Tests
  15.4.4 Lung Biopsy
  15.4.5 Others
 15.5 Historic and Forecasted Market Size By Disease Type
  15.5.1 Interstitial Pneumonia
  15.5.2 Idiopathic Pulmonary Fibrosis
  15.5.3 Hypersensitivity Pneumonitis
  15.5.4 Sarcoidosis
  15.5.5 Asbestosis
 15.6 Historic and Forecasted Market Size By Treatment
  15.6.1 Medications
  15.6.2 Pulmonary Rehabilitation
  15.6.3 Oxygen Therapy
  15.6.4 Surgery
 15.7 Historic and Forecasted Market Size By Route Of Administration
  15.7.1 Oral
  15.7.2 Injectable
  15.7.3 Others
 15.8 Historic and Forecast Market Size by Country
  15.8.1 Brazil
  15.8.2 Argentina
  15.8.3 Rest of SA

Chapter 16 Investment Analysis

Chapter 17 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. INTERSTITIAL LUNG DISEASE TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. INTERSTITIAL LUNG DISEASE TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. INTERSTITIAL LUNG DISEASE TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. INTERSTITIAL LUNG DISEASE TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. INTERSTITIAL LUNG DISEASE TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. INTERSTITIAL LUNG DISEASE TREATMENT MARKET BY TYPE
TABLE 008. IMAGING TESTS MARKET OVERVIEW (2016-2028)
TABLE 009. BLOOD TESTS MARKET OVERVIEW (2016-2028)
TABLE 010. LUNG FUNCTION TESTS MARKET OVERVIEW (2016-2028)
TABLE 011. LUNG BIOPSY MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. INTERSTITIAL LUNG DISEASE TREATMENT MARKET BY DISEASE TYPE
TABLE 014. INTERSTITIAL PNEUMONIA MARKET OVERVIEW (2016-2028)
TABLE 015. IDIOPATHIC PULMONARY FIBROSIS MARKET OVERVIEW (2016-2028)
TABLE 016. HYPERSENSITIVITY PNEUMONITIS MARKET OVERVIEW (2016-2028)
TABLE 017. SARCOIDOSIS MARKET OVERVIEW (2016-2028)
TABLE 018. ASBESTOSIS MARKET OVERVIEW (2016-2028)
TABLE 019. INTERSTITIAL LUNG DISEASE TREATMENT MARKET BY TREATMENT
TABLE 020. MEDICATIONS MARKET OVERVIEW (2016-2028)
TABLE 021. PULMONARY REHABILITATION MARKET OVERVIEW (2016-2028)
TABLE 022. OXYGEN THERAPY MARKET OVERVIEW (2016-2028)
TABLE 023. SURGERY MARKET OVERVIEW (2016-2028)
TABLE 024. INTERSTITIAL LUNG DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION
TABLE 025. ORAL MARKET OVERVIEW (2016-2028)
TABLE 026. INJECTABLE MARKET OVERVIEW (2016-2028)
TABLE 027. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 028. NORTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TYPE (2016-2028)
TABLE 029. NORTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 030. NORTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TREATMENT (2016-2028)
TABLE 031. NORTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 032. N INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 033. EUROPE INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TYPE (2016-2028)
TABLE 034. EUROPE INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 035. EUROPE INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TREATMENT (2016-2028)
TABLE 036. EUROPE INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 037. INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 038. ASIA PACIFIC INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TYPE (2016-2028)
TABLE 039. ASIA PACIFIC INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 040. ASIA PACIFIC INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TREATMENT (2016-2028)
TABLE 041. ASIA PACIFIC INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 042. INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TYPE (2016-2028)
TABLE 044. MIDDLE EAST & AFRICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 045. MIDDLE EAST & AFRICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TREATMENT (2016-2028)
TABLE 046. MIDDLE EAST & AFRICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 047. INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 048. SOUTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TYPE (2016-2028)
TABLE 049. SOUTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 050. SOUTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY TREATMENT (2016-2028)
TABLE 051. SOUTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 052. INTERSTITIAL LUNG DISEASE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 053. F. HOFFMAN - LA ROCHE LTD.: SNAPSHOT
TABLE 054. F. HOFFMAN - LA ROCHE LTD.: BUSINESS PERFORMANCE
TABLE 055. F. HOFFMAN - LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 056. F. HOFFMAN - LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. MERCK SHARP & DOHME CORP.: SNAPSHOT
TABLE 057. MERCK SHARP & DOHME CORP.: BUSINESS PERFORMANCE
TABLE 058. MERCK SHARP & DOHME CORP.: PRODUCT PORTFOLIO
TABLE 059. MERCK SHARP & DOHME CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SNAPSHOT
TABLE 060. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS PERFORMANCE
TABLE 061. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 062. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. J.B. CHEMICALS & PHARMACEUTICAL: SNAPSHOT
TABLE 063. J.B. CHEMICALS & PHARMACEUTICAL: BUSINESS PERFORMANCE
TABLE 064. J.B. CHEMICALS & PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 065. J.B. CHEMICALS & PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. GALECTO INC.: SNAPSHOT
TABLE 066. GALECTO INC.: BUSINESS PERFORMANCE
TABLE 067. GALECTO INC.: PRODUCT PORTFOLIO
TABLE 068. GALECTO INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. CIPLA LTD.: SNAPSHOT
TABLE 069. CIPLA LTD.: BUSINESS PERFORMANCE
TABLE 070. CIPLA LTD.: PRODUCT PORTFOLIO
TABLE 071. CIPLA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. GLENMARK PHARMA: SNAPSHOT
TABLE 072. GLENMARK PHARMA: BUSINESS PERFORMANCE
TABLE 073. GLENMARK PHARMA: PRODUCT PORTFOLIO
TABLE 074. GLENMARK PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. GILEAD SCIENCES INC.: SNAPSHOT
TABLE 075. GILEAD SCIENCES INC.: BUSINESS PERFORMANCE
TABLE 076. GILEAD SCIENCES INC.: PRODUCT PORTFOLIO
TABLE 077. GILEAD SCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. BRISTOL-MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 078. BRISTOL-MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 079. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 080. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. FIBROGEN INC.: SNAPSHOT
TABLE 081. FIBROGEN INC.: BUSINESS PERFORMANCE
TABLE 082. FIBROGEN INC.: PRODUCT PORTFOLIO
TABLE 083. FIBROGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. LIMINAL BIOSCIENCES: SNAPSHOT
TABLE 084. LIMINAL BIOSCIENCES: BUSINESS PERFORMANCE
TABLE 085. LIMINAL BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 086. LIMINAL BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. OTHERS MAJOR PLAYERS: SNAPSHOT
TABLE 087. OTHERS MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 088. OTHERS MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 089. OTHERS MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY TYPE
FIGURE 012. IMAGING TESTS MARKET OVERVIEW (2016-2028)
FIGURE 013. BLOOD TESTS MARKET OVERVIEW (2016-2028)
FIGURE 014. LUNG FUNCTION TESTS MARKET OVERVIEW (2016-2028)
FIGURE 015. LUNG BIOPSY MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY DISEASE TYPE
FIGURE 018. INTERSTITIAL PNEUMONIA MARKET OVERVIEW (2016-2028)
FIGURE 019. IDIOPATHIC PULMONARY FIBROSIS MARKET OVERVIEW (2016-2028)
FIGURE 020. HYPERSENSITIVITY PNEUMONITIS MARKET OVERVIEW (2016-2028)
FIGURE 021. SARCOIDOSIS MARKET OVERVIEW (2016-2028)
FIGURE 022. ASBESTOSIS MARKET OVERVIEW (2016-2028)
FIGURE 023. INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY TREATMENT
FIGURE 024. MEDICATIONS MARKET OVERVIEW (2016-2028)
FIGURE 025. PULMONARY REHABILITATION MARKET OVERVIEW (2016-2028)
FIGURE 026. OXYGEN THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 027. SURGERY MARKET OVERVIEW (2016-2028)
FIGURE 028. INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 029. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 030. INJECTABLE MARKET OVERVIEW (2016-2028)
FIGURE 031. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 032. NORTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. EUROPE INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 034. ASIA PACIFIC INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 035. MIDDLE EAST & AFRICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 036. SOUTH AMERICA INTERSTITIAL LUNG DISEASE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)